Clinical trials: Adenosine
Psoriasis
Study to Assess the Safety and Tolerability of PBF-1650 in Healthy Volunteers.
Single center, randomized, double-blind, placebo-controlled clinical study to assess the safety and tolerability of PBF-1650 in order to obtain the Maximum Tolerated Dose (MTD).
- Trial name
- ADENOIMMUNE (NCT03798236)
- Testing
- PBF-1650 oral capsules
- Where
- Spain
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Palobiofarma SL
Moderate Hepatic Impairment
A Study of TMC207 in Patients With Moderately Impaired Hepatic Function
The purpose of this study is to assess the pharmacokinetics (what the body does to the medication), safety and tolerability of TMC207 and its N-monodesmethyl metabolite (M2) in healthy participants and in patients with moderate…
- Trial name
- NCT01012284
- Testing
- TMC207
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Tibotec BVBA
Healthy Subjects
Effect of Oral Adenosine-triphosphate (ATP) on Human Muscle Performance
Adenosine-triphosphate (ATP) serves as the sole energy source for muscle contraction. Therefore human performance of brief maximal exercise is limited, in part, by the availability of ATP to the contracting muscle.
- Trial name
- NCT01141504
- Testing
- PeakATP 250, PeakATP 400, PeakATP 400 plus proprietary blend
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Metabolic Technologies Inc.
Healthy Experienced Weight Training Males
The Effects of HMB, ATP, and HMB Plus ATP on Muscle Mass, Strength, and Power in Resistance Trained Athletes
The purpose of this study is to determine the effects of 12 weeks of HMB free acid gel, ATP, and HMB free acid gel plus ATP supplementation in trained individuals during a periodized training program on skeletal muscle…
- Trial name
- NCT01508338
- Testing
- HMB, Peak ATP and HMB, ATP
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Metabolic Technologies Inc.
Blood Flow Speed, Coronary Flow Velocity
Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects.
The purpose of this study is to determine if Ticagrelor increases the Adenosin induced coronary blood flow velocity.
- Trial name
- NCT01226602
- Testing
- AZD6140
- Where
- Sweden
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Health
Phase I Dose-Escalation Study to Evaluate Tolerability, Safety & PK of INO-8875 in Healthy Older-Adult Volunteers
The purpose of this study is to evaluate how tolerable and safe it is to give INO-8875 eye drops at different concentrations to normal older healthy adult volunteers for two weeks.
- Trial name
- NCT01123772
- Testing
- INO-8875
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Inotek Pharmaceuticals Corporation
Healthy Volunteer/DDI Study
A Study to Assess the Effect of Fluvoxamine and Smoking on Pharmacokinetics ( the Movement of Drugs Within the Body) of AZD4635 in Healthy Volunteers
This study is a Phase I, open-label, non-randomized, 2-period, fixed-sequence study in healthy volunteers who are either smokers or non-smokers, performed at a single Clinical Unit.
- Trial name
- NCT04478513
- Testing
- AZD4635, Fluvoxamine
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Parkinson's Disease
A Study in Healthy Male Volunteers to Investigate a New Drug for the Treatment of Parkinson's Disease
The main purpose of the study is to identify the best dose of V81444 to use in future trials in patients with Parkinson's disease.
- Trial name
- NCT02764892
- Testing
- V81444
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Vernalis (R&D) Ltd
Healthy
Using PET Scans to Study Brain Receptor Occupancy of BIIB014 in Healthy Male Volunteers
To establish the extent to which BIIB014, following 8 to 12 consecutive days of dosing at selected dose levels, occupies the brain's A2A receptors. Receptor occupancy will be assessed by PET scanning using a radiolabelled tracer.
- Trial name
- NCT00531193
- Testing
- BIIB014, [11C]SCH442416
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Biogen
Glaucoma
"First-in-human" Study To Assess the Safety and Tolerability of PBF-677 in Healthy Volunteers
The proposed trial a "Randomized, Double Blind, Placebo Controlled "first in-human" Study to Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-677 in Male Healthy Volunteers" (Protocol Code No:CUNFI-1509…
- Trial name
- NCT02639975
- Testing
- PBF-677
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Palobiofarma SL
Platelet Aggregation
A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540
This study is designed to provide data on platelet aggregation of PA32540 plus clopidogrel dosed separately compared to EC aspirin 81 mg plus EC omeprazole 40 mg plus clopidogrel dosed concomitantly.
- Trial name
- NCT01557335
- Testing
- Plavix® and PA32540, EC aspirin (Bayer®) ,EC omeprazole (Prilosec®) , Clopidogrel (Plavix®)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- POZEN
Platelet Aggregation, ADP Blockers
Aggreguide A-100 ADP Assay Evaluation
The study is to characterize the AggreGuide ADP Assay's performance.
- Trial name
- NCT02112539
- Testing
- platelet aggregation measurement
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Aggredyne, Inc.
Risk Factor, Cardiovascular, Platelet Dysfunction Due to Drugs
Study of AggreGuide A-100 (ADP) Assay
Study to evaluate the performance of the AggreGuide A-100 ADP assay for detection of platelet dysfunction caused by P2Y12 inhibitor antiplatelet therapy.
- Trial name
- NCT03111420
- Testing
- P2Y12 inhibitor, Platelet function test
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Aggredyne, Inc.